

Announcement of FY 2008 Results and Guidance 2009

Analyst Conference February 17, 2009 | 3:00 p.m. CET

Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO

Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.



Agenda

■ Key Facts FY 2008

Dr. Axel Herberg, CEO

Financial Overview FY 2008

Hans-Jürgen Wiecha, CFO

Guidance FY 2009

Dr. Axel Herberg, CEO




Successful performance of operations in FY 2008 Guidance accomplished

- Net sales growth of 10.7% to EUR 1,060.1m (at constant FX rate: +12.8%)
- Adjusted EBITDA rose by 13.7% to EUR 206.4m
- Adjusted EBITDA margin grew from 19.0% to 19.5%
- Adjusted EPS improved markedly from EUR 1.34 by 36.6% to EUR 1.83
- Proposed dividend of EUR 0.40 per share



Positive sales and adjusted EBITDA trend established





All divisions contributed to sales and margin growth

Plastic Systems:Medical Plastic Systems remains tPlastic Packaging: acquisitions sucDivestment of Consumer Healthce	ccessfully integrated
 Moulded Glass: Further sales growth above mark pharma bottles and cosmetics Higher margin due to contributio productivity improvements 	-
 Life Science Division benefited from strong m Margin improvement by transfer product range 	arket position of production and streamlining of

Agenda

Key Facts FY 2008

Dr. Axel Herberg, CEO

■ Financial Overview FY 2008


Hans-Jürgen Wiecha, CFO

Guidance FY 2009

Dr. Axel Herberg, CEO




Group: Increased sales and earnings across all divisions







Tubular Glass: RTF syringes remain key growth driver



Plastic Systems: Growth in sales and earnings fueled by Medical Plastic Systems and two acquisitions




Moulded Glass: Higher growth rate compared with the market





Life Science Research: New setup starts to bear fruits





Key operating metrics show positive development

EUR m	FY 2008: Dec 1, 2007 – Nov 30, 2008	FY 2007: Dec 1, 2006 – Nov 30, 2007	
Adjusted EBITDA ¹	206.4	181.6	+13.7%
EBITDA	204.9	152.3	+34.5%
Profit from operations	61.0	53.3	+14.4%
Net income before taxes	17.3	-24.3	>100%
Net income	4.5	0.8	>100%
Adjusted net income ²	61.4	44.3	+38.6%
EPS	0.02	-0.04	>100%
Adjusted EPS ³	1.83	1.34	+36.6%

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses
 ² Adjusted net income: consolidated profit before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects
 ³ Adjusted net income after minorities divided by 31.4m shares




Financial stability is our foundation

EUR m	FY 2008 as of Nov 30, 2008	FY 2007 as of Nov 30, 2007
Equity Equity ratio in %	479.1 31.1	499.9 34.8
Net Working Capital ¹ in % of LTM net sales	163.0 15.4	179.8 18.8
Net financial debt ²	421.6	390.6
Adjusted EBITDA leverage ³	2.0	2.2
	Dec 1, 2007 – Nov 30, 2008	Dec 1, 2006 – Nov 30, 2007
CF from operating activities	165.3	54.1
Capital expenditure	107.8	98.9

¹ Inventories, trade receivables and prepayments on account of orders less trade payables and payments received on account of orders
 ² Total amount of debt less cash and cash equivalents
 ³ The ratio of interest bearing net debt to adjusted EBITDA of the preceding 12 months

Adjusted EBITDA leverage with favorable development despite recent acquisitions and high investments





Secured long-term financing structure; liquidity reserves through EUR 175m committed revolver

R m ¹	Interest rate	Due by
421.6		
126.0	7.9%; Fixed coupon	2015
256.4	5.7%; Hedged 100% until Sep 2010	2012 / 2013
53.8 53.4 27.1 95.1	55bps over Euribor/Libor; Headroom: EUR 121m 6.4% (average) 5.5% (average)	2012 / 2013
	421.6 126.0 256.4 53.8 53.4	421.6 126.0 7.9%; Fixed coupon 256.4 5.7%; Hedged 100% until Sep 2010 53.8 55bps over Euribor/Libor; Headroom: EUR 121m 6.4% (average)

¹ As of November 30, 2008

Agenda

Key Facts FY 2008

Dr. Axel Herberg, CEO

Financial Overview FY 2008


Hans-Jürgen Wiecha, CFO

■ Guidance FY 2009

Dr. Axel Herberg, CEO



Guidance FY 2009: Core activities (excl. Technical Plastic Systems)





Assumptions for sales and adjusted EBITDA margin guidance (excl. Technical Plastic Systems)

Sales growth of 6-7%

Guidance includes the following effects (vs. FY 2008):

- Exchange rate: EUR 1.00 = USD 1.48 actual FY 2008 Exchange rate: EUR 1.00 = USD 1.30 budget FY 2009
- Slower sales in high-end cosmetics and temporary destocking effects
- Acquisitions & divestitures





Adj. EBITDA margin of 19.0 - 19.2%

Guidance includes the following effects (vs. FY 2008):

- Furnace repairs
- Ramp up of new products
- Residual costs of destocking effects
- Temporary replacement of cosmetics with lower margin products

approximately
 -1.5 percentage points



Assumptions Technical Plastic Systems FY 2009

Sales

EUR 35-45m (FY 2008: EUR 63m)

Adjusted EBITDA

■ EUR 0 to -3m (FY 2008: mid single digit EBITDA margin)

Cash Flow

Neutral in 2009



Further growth based on stability of business model

- Strong focus on Pharma & Life Science Industry
- Leading market positions in attractive niche markets
- Major share of sales out of prescription drugs
- Highly diversified customer base
- High barriers to entry due to regulatory environment

Financial Calendar	
April 2, 2009	Interim Report 1st Quarter 2009
April 29, 2009	Annual General Meeting
July 15, 2009	Interim Report 2nd Quarter 2009
October 15, 2009	Interim Report 3rd Quarter 2009



Investor Relations Contact Details Phone +49 211 6181-257 +49 211 6181-121 **Fax** gerresheimer.ir@gerresheimer.com E-mail ■ IR website www.gerresheimer.com/ir

Backup Q4 2008: Gerresheimer Group

